 |
| PI-RADS v2.0 vs. v2.1: MRI Interpretation Impact on Prostate Cancer Grade Assessment |
On September 22, 2023, an accepted manuscript published in the American Journal of Roentgenology (AJR) shed light on the rates of upgrade and downgrade in patients undergoing targeted biopsy to radical prostatectomy. The study revealed that these rates remained largely unchanged when comparing patients whose MRI examinations were clinically interpreted using either PI-RADS Version v2.0 or v2.1.
The corresponding author of the study, Dr. Baris Turkbey, hailing from the Molecular Imaging Branch of the National Cancer Institute at the National Institutes of Health in Bethesda, MD, concluded that the introduction of the latest PI-RADS update failed to rectify the disparities in assessing prostate cancer grade between targeted biopsy and surgical procedures.
Dr. Turkbey and his colleagues conducted a retrospective post-hoc analysis involving patients who had undergone 3-T prostate MRI at a single institution between May 2015 and March 2023 as part of prospective clinical trials. Among these trial participants, the researchers identified those who had received MRI examinations followed by MRI/ultrasound-fusion guided targeted biopsies and subsequently underwent radical prostatectomies within a 1-year timeframe. A genitourinary radiologist performed the clinical interpretations of the MRI examinations, employing PI-RADS v2.0 from May 2015 to March 2019 and PI-RADS v2.1 from April 2019 to March 2023.
Ultimately, the study found that there were no significant differences between patients whose MRI results were interpreted using PI-RADS v2.0 and those interpreted with PI-RADS v2.1 in terms of upgrade rates (29% vs. 22%, p = .15), downgrade rates (19% vs. 21%, p = .76), clinically significant upgrade rates (14% vs. 10%, p = .27), or clinically significant downgrade rates (1% vs. 1%, p >.99) from targeted biopsy to radical prostatectomy grade group.
إرسال تعليق